Alnylam Pharmaceuticals Inc. (ALNY) Stock Price Target Moved to $89.00 at Chardan Capital

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) shares were down on Wednesday Nov 30 with lower trade volume than normal after a number of analysts weighed in on the investing value of the stock, increasing the price target of stock.

Meanwhile, the Dow Jones Industrial Average hit an intraday record after opening higher Wednesday, led by the energy sector as hopes rose that the world’s major oil producers are near a deal on limiting output.

The benchmark S&P 500 and Dow were on track to post their largest monthly gains since March.

The S&P 500 SPX, +0.22% gained 5 points, or 0.2%, to 2,209. The Dow Jones Industrial Average DJIA, +0.41% added 62 points, or 0.3%, to 19,184, trading in record territory. The Nasdaq Composite COMP, -0.08% was 7 points, or 0.1%, higher at 5,386.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) had its price target increased by equities researchers at Chardan Capital from $73.00 to $89.00. With a rating of Buy on the stock, the company has a 52-week high of $109.10. The one-year price target of $62.93 is higher than the opening price of $46.80, causing a fair amount of other analysts to report on the stock recently.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) shares last traded at $46.00, a dip of $0.04 per share or -0.08% compared to the previous closing price. Opening at $46.80, they fluctuated from $45.44 and $46.87 throughout the day.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) currently has a market cap of 3.95B.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Average Daily Trading Volume

164,509 shares traded hands yesterday, below the average, out of a total float 58,917,000. Swing traders often use increases in trading volume to identify heavy volume growth or circulation by institutional investors, so look for trading volume to pick up in the coming days.

As with all possible breakouts, investors look for volume to be at least 40%-50% greater than normal on the breakout to indicate that fund managers and other professional investors are jumping in.

Institutional sponsorship commonly refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These professional investors have substantial teams of analysts that research thousands of stocks, so it is good corroboration to see them taking a postion in a stock you’re considering.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By spotting trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.

With that in mind, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) now has a 50-day MA of $40.00 and 200-day MA of $59.82. It has traded in a 52-week range between $31.38 – 109.100 and today’s last price is 57.84%% lower than the 52 week high of $109.10.

Indeed, earnings growth is among the most important things to look at in regards to stock investing and, accordingly, investors look for companies that have been successful at growing their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *